Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Ulrich Aldag

Karsten Henco

Manfred Eigen

Rudolf Rigler

Charles Weissmann

Heinrich M. Schulte

Freimut Leidenberger

Evotec SE

GC Therapeutics harnesses an induced pluripotent stem cell (iPSC) cellular programming platform to improve patient access across various therapeutic areas, focusing on gastrointestinal, neurological, and immunological diseases.

GC Therapeutics

Körber is an international technology group that focuses on transforming entrepreneurial thinking into customer success and shaping technological change. The company employs over 12,000 people at more than 100 locations worldwide.

Körber

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

Metric
Company Name	Evotec SE	GC Therapeutics	Körber	Sartorius Aktiengesellschaft
Symbol	EVT			SRT
MSH ID	COM:EVOTEC	COM:GC-TX	COM:KOERBER	COM:SARTORIUS
Market	STOCKS	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare	Healthcare & Health Services	Technology	Healthcare
Industry	Drug Manufacturers - Specialty & Generic	Biotechnology	Technology and Engineering	Medical - Instruments & Supplies
Country	DE	US	DE	DE
Stage		Series A
Employee Count	5.05K			14.61K
Website	evotec.com	gc-tx.com	koerber.com	sartorius.com
LinkedIn			k%C3%B6rber	sartorius
Founders

Metric
Market Cap	1.68B		15.56B
Enterprise Value
Monthly Web Traffic	47.49K	1.68K	1.07M
Web Traffic Growth	0.11	-0.43	1.47
Valuation
Raised Capital		65M

Metric
Revenue	825.37M	3.59B
Revenue (LTM)
Revenue (NTM)
Gross Profit	184.89M	1.66B
EBITDA	-7.57M	890.51M
Operating Income	-113.11M	528.96M
Net Income	-88.63M	357.53M
EPS	-0.50	5.23
Diluted EPS	-0.50	5.23
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.27	0.46
Operating Profit Margin	-0.00	0.16
EBITDA Margin	-0.01	0.25
Net Profit Margin	-0.11	0.09
Return on Equity	-0.07	0.15
Return on Assets	-0.04	0.03
Return on Capital Employed	-0.00	0.07

COM:EVOTEC

Evotec SE

Last Close

8.50

25/11 09:24

Market Cap

1.59B

Beta: -

Volume Today

564.94K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-13.33	41.01
P/B Ratio	1.97	8.67
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.01	6.48
EV Multiple	70.97	19.08

Metric
Days Sales Outstanding	124.70	42.10
Days Payables Outstanding	61.49	91.49
Days Inventory Outstanding	20.58	206.95
Operating Cycle	141.03	260.52
Cash Conversion Cycle	93.12	181.83
Asset Turnover	0.39	0.35

Metric
Operating Cash Flow	35.86M	901.60M
Free Cash Flow	-192.28M	310.43M
Cash Flow to Debt	0.05	0.18
Operating Cash Flow/Sales	0.04	0.25
Free Cash Flow Yield	0.01	0.01

Metric
Cash & Equivalents	539.64M	400.52M
Accounts Receivable		178.08M
Inventory	32.63M	1.10B
Goodwill	291.13M	3.61B
Debt to Capitalization	0.36	0.72
Debt to Assets	0.22	0.54
Current Ratio	3.18	1.49
Quick Ratio	1.93	1.19

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.10	0.05
SG&A to Revenue	0.04	0.05